Fziomed has surpassed treating one million patients worldwide across its product portfolio over the past 20+ years.
The synthetic, clear, absorbable gels are based on the company’s proprietary dual-polymer technology platform, which provides a temporary, physical separation of tissues during the body’s natural healing process. Clinical use of these products has been associated with improved patient outcomes, including reduced adhesion formation, improved fertility rates, decreased postoperative pain, and improved neurological symptoms.
Fziomed’s adhesion barrier products have been used clinically since 2002 and are marketed in more than seventy countries under various brand names.
Fziomed has surpassed treating one million patients worldwide across its product portfolio over the past 20+ years.
The synthetic, clear, absorbable gels are based on the company's proprietary dual-polymer technology platform, which provides a temporary, physical separation of tissues during the body's natural healing process. Clinical use of...
Fziomed has surpassed treating one million patients worldwide across its product portfolio over the past 20+ years.
The synthetic, clear, absorbable gels are based on the company’s proprietary dual-polymer technology platform, which provides a temporary, physical separation of tissues during the body’s natural healing process. Clinical use of these products has been associated with improved patient outcomes, including reduced adhesion formation, improved fertility rates, decreased postoperative pain, and improved neurological symptoms.
Fziomed’s adhesion barrier products have been used clinically since 2002 and are marketed in more than seventy countries under various brand names.
Copy to clipboard 
